RU2346702C2 - Применение антител к ctla-4 - Google Patents

Применение антител к ctla-4 Download PDF

Info

Publication number
RU2346702C2
RU2346702C2 RU2006134045/14A RU2006134045A RU2346702C2 RU 2346702 C2 RU2346702 C2 RU 2346702C2 RU 2006134045/14 A RU2006134045/14 A RU 2006134045/14A RU 2006134045 A RU2006134045 A RU 2006134045A RU 2346702 C2 RU2346702 C2 RU 2346702C2
Authority
RU
Russia
Prior art keywords
cancer
antibody
amino acid
heavy
acid sequences
Prior art date
Application number
RU2006134045/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2006134045A (ru
Inventor
Хесус ГОМЕС-НАВАРРО (US)
Хесус ГОМЕС-НАВАРРО
Дуглас Чарльз ХАНСОН (US)
Дуглас Чарльз Хансон
Ейлин Эллиот МЮЛЛЕР (US)
Ейлин Эллиот Мюллер
Деннис Алан НОЭ (US)
Деннис Алан НОЭ
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of RU2006134045A publication Critical patent/RU2006134045A/ru
Application granted granted Critical
Publication of RU2346702C2 publication Critical patent/RU2346702C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2006134045/14A 2004-03-26 2005-03-14 Применение антител к ctla-4 RU2346702C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55680104P 2004-03-26 2004-03-26
US60/556,801 2004-03-26

Publications (2)

Publication Number Publication Date
RU2006134045A RU2006134045A (ru) 2008-03-27
RU2346702C2 true RU2346702C2 (ru) 2009-02-20

Family

ID=35056778

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006134045/14A RU2346702C2 (ru) 2004-03-26 2005-03-14 Применение антител к ctla-4

Country Status (15)

Country Link
US (1) US20050226875A1 (enExample)
EP (1) EP1732600A2 (enExample)
JP (1) JP2007530526A (enExample)
KR (1) KR100845354B1 (enExample)
CN (1) CN1964739A (enExample)
AR (1) AR049480A1 (enExample)
AU (1) AU2005225227A1 (enExample)
BR (1) BRPI0509274A (enExample)
CA (1) CA2560919A1 (enExample)
IL (1) IL177602A0 (enExample)
NO (1) NO20064854L (enExample)
RU (1) RU2346702C2 (enExample)
TW (2) TW200602078A (enExample)
WO (1) WO2005092380A2 (enExample)
ZA (1) ZA200607544B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034764B2 (en) 2017-09-21 2021-06-15 Eucure (Beijing) Biopharma Co., Ltd Anti-CTLA4 antibodies and uses thereof
RU2756100C1 (ru) * 2017-12-20 2021-09-28 Харбор Байомед (Шанхай) Ко., Лтд Антитела, связывающие ctla-4, и их применение
RU2779312C2 (ru) * 2017-09-21 2022-09-06 Юкьюр (Бэйцзин) Байофарма Ко., Лтд Антитела против ctla4 и их применения

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053690A1 (es) * 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
EP2365823B1 (en) 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
ES2668645T3 (es) 2010-02-08 2018-05-21 Agensys, Inc. Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
CN105907713A (zh) 2010-09-08 2016-08-31 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
CN103270050A (zh) * 2010-09-08 2013-08-28 耶达研究及发展有限公司 用于稳定和长期移植的免疫抑制药物组合
CN105567717B (zh) 2010-09-29 2019-10-29 艾更斯司股份有限公司 结合于191p4d12蛋白的抗体药物偶联物(adc)
WO2013013029A1 (en) 2011-07-19 2013-01-24 The Board Of Trustees Of The University Of Illinois Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
CN103930130B (zh) 2011-09-08 2016-07-06 耶达研究及发展有限公司 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
PL2887959T3 (pl) 2012-08-23 2019-04-30 Agensys Inc Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7
WO2015017552A1 (en) 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
JP6917902B2 (ja) * 2015-02-13 2021-08-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
KR102790429B1 (ko) 2015-03-09 2025-04-04 어젠시스 인코포레이티드 Flt3 단백질에 결합하는 항체 약물 콘쥬게이트(adc)
US10787516B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
WO2016187356A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2017009853A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
RU2619208C2 (ru) * 2015-10-08 2017-05-12 ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
US10947317B2 (en) 2016-03-15 2021-03-16 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
MX2021006430A (es) 2018-12-03 2021-09-14 Agensys Inc Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas.
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
TW202206592A (zh) 2020-04-22 2022-02-16 美商艾歐凡斯生物治療公司 用於協調產製供病患特異性免疫治療之細胞的系統和方法
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AU2022292462A1 (en) 2021-06-18 2023-12-07 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
IL320733A (en) 2022-11-21 2025-07-01 Iovance Biotherapeutics Inc Two-dimensional processes for expanding tumor-infiltrating lymphocytes and treatments thereof
TW202504637A (zh) 2023-06-13 2025-02-01 美商艾德森特克斯治療股份有限公司 與結合至nectin-4蛋白之抗體及抗體藥物結合物(adc)相關之方法及組合物
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203682C2 (ru) * 1999-08-30 2003-05-10 Джапан Тобакко Инк. Фармацевтическая композиция для лечения иммунных заболеваний

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
SG143018A1 (en) * 1998-12-23 2008-06-27 Pfizer Human monoclonal antibodies to ctla-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
ATE552849T1 (de) * 2002-04-12 2012-04-15 Medarex Inc Behandlungsverfahren unter verwendung von ctla-4 antikörpern

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203682C2 (ru) * 1999-08-30 2003-05-10 Джапан Тобакко Инк. Фармацевтическая композиция для лечения иммунных заболеваний

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
c.50-56. *
MOKYR MB et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice // Cancer Res. 1998 Dec 1; 58(23):5301-4. _ реферат, он-лайн [Найдено в Интернет на www.pubmed.com 21.11.2007], PMID: 9850053 [PubMed - indexed for MEDLINE]. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034764B2 (en) 2017-09-21 2021-06-15 Eucure (Beijing) Biopharma Co., Ltd Anti-CTLA4 antibodies and uses thereof
RU2779312C2 (ru) * 2017-09-21 2022-09-06 Юкьюр (Бэйцзин) Байофарма Ко., Лтд Антитела против ctla4 и их применения
US12054547B2 (en) 2017-09-21 2024-08-06 Eucure (Beijing) Biopharma Co., Ltd. Anti-CTLA4 antibodies and uses thereof
RU2756100C1 (ru) * 2017-12-20 2021-09-28 Харбор Байомед (Шанхай) Ко., Лтд Антитела, связывающие ctla-4, и их применение
US12240905B2 (en) 2017-12-20 2025-03-04 Harbour Biomed (Shanghai) Co., Ltd. Antibodies binding CTLA-4 and uses thereof
RU2822460C2 (ru) * 2019-07-15 2024-07-05 Интервет Интернэшнл Б.В. Канинизированные антитела против человеческого ctla-4

Also Published As

Publication number Publication date
IL177602A0 (en) 2006-12-10
ZA200607544B (en) 2008-07-30
BRPI0509274A (pt) 2007-09-04
RU2006134045A (ru) 2008-03-27
KR100845354B1 (ko) 2008-07-09
WO2005092380A3 (en) 2006-06-15
NO20064854L (no) 2006-12-22
EP1732600A2 (en) 2006-12-20
US20050226875A1 (en) 2005-10-13
CN1964739A (zh) 2007-05-16
KR20070007114A (ko) 2007-01-12
JP2007530526A (ja) 2007-11-01
AU2005225227A1 (en) 2005-10-06
CA2560919A1 (en) 2005-10-06
TW200829271A (en) 2008-07-16
WO2005092380A2 (en) 2005-10-06
TW200602078A (en) 2006-01-16
AR049480A1 (es) 2006-08-09

Similar Documents

Publication Publication Date Title
RU2346702C2 (ru) Применение антител к ctla-4
JP2007530526A5 (enExample)
RU2010135087A (ru) Многоклональные антитела человека к белку программируемой смерти 1 (pd) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2018027952A5 (enExample)
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
JP2021502104A5 (enExample)
FI3631454T3 (fi) Lag-3-positiivisten kasvainten hoitaminen
JP2018524300A5 (ja) 組成物、抗体および結合性フラグメント
RU2008152332A (ru) Антитела, распознающие содержащий углеводы эпитоп на cd43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
JP2010508847A5 (enExample)
RU2012117619A (ru) ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
JP2024059609A5 (enExample)
RU2016147206A (ru) Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
RU2014108043A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
JPWO2019189780A5 (enExample)
RU2016134843A (ru) Антитела к ceacam1 и способы их использования
RU2018100545A (ru) Способы и антитела для модуляции иммунного ответа
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
RU2014108049A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2014102935A (ru) Кризотиниб для применения в лечении рака
RU2012137502A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2008122471A (ru) Способ лечения аномального роста клеток
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090315